Comprehensive Genome profile testing in head and neck cancer

Area of Science:

• Oncology
• Genomics
• Cancer Research

Background:

• Head and neck cancer (HNC) presents limited chemotherapy options.
• Comprehensive genomic profiling (CGP) is increasingly utilized in clinical settings.
• Understanding the genomic landscape of HNC is crucial for treatment advancements.

Purpose of the Study:

• To evaluate the utility of CGP in diagnosing and treating HNC.
• To identify common gene mutations and analyze tumor mutational burden (TMB) in HNC patients.
• To investigate the correlation between genetic alterations, TMB, and patient prognosis.

Main Methods:

• CGP testing was performed on 29 HNC patients.
• Analysis included gene mutation types, tumor mutational burden (TMB), and survival rates.
• Correlation between genetic mutations, TMB, and prognosis was investigated.

Main Results:

• TP53 (48.3%), CDKN2A (27.6%), and CDKN2B (17.2%) were among the frequently mutated genes.
• Mutations in TP53, CDKN2A, and CDKN2B were associated with decreased survival.
• TMB-high (17.2%) cases, predominantly oropharyngeal cancer, showed better survival with immune checkpoint inhibitors in squamous cell carcinoma.

Conclusions:

• CGP detected numerous gene mutations in HNC, with several correlating with prognosis.
• While direct treatment based on CGP was not performed, findings highlight CGP's diagnostic and prognostic value.
• TMB shows potential as a predictive biomarker for immune checkpoint inhibitor therapy in HNC squamous cell carcinoma.